| Title |
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
|
|---|---|
| Published in |
Acta Diabetologica, August 2016
|
| DOI | 10.1007/s00592-016-0892-7 |
| Pubmed ID | |
| Authors |
Matteo Monami, Ilaria Dicembrini, Edoardo Mannucci |
| Abstract |
EMPAREG OUTCOME study showed a reduction in cardiovascular events in patients treated with the sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin, as compared to placebo. Other drugs of the same class are currently been investigated for cardiovascular outcomes. In the meanwhile, a re-analysis of data collected in available studies can add relevant insight. A MEDLINE search for SGLT-2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, ertugliflozin, luseogliflozin) was performed, collecting all randomized trials up to November 16, 2015. All trials with a duration of treatment ≥12 weeks, enrolling patients with type 2 diabetes, comparing a SGLT2i with placebo or other comparators were included. The principal outcome was the effect of SGLT2i on all-cause and cardiovascular mortality. Secondary endpoints were myocardial infarction and stroke. Mantel-Haenszel odds ratio with 95 % confidence interval (MH-OR) was calculated. A total of 71 trials were included (31,199 and 16,088 patients in SGLT2i and comparator groups). Treatment with SGLT2i was associated with a significant reduction in all-cause mortality (MH-OR 0.70 [0.59-0.83], p < 0.001), cardiovascular mortality (MH-OR 0.43 [0.36-0.53], p < 0.001), and myocardial infarction (MH-OR 0.77 [0.63-0.94], p < 0.01), but not stroke (MH-OR 1.09 [0.86-1.38], p = 0.50), with no apparent difference across molecules (after excluding cardiovascular outcome trials). Available data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 38% |
| United Kingdom | 2 | 13% |
| Malaysia | 1 | 6% |
| India | 1 | 6% |
| Canada | 1 | 6% |
| Unknown | 5 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 50% |
| Scientists | 5 | 31% |
| Practitioners (doctors, other healthcare professionals) | 3 | 19% |
Mendeley readers
The data shown below were compiled from readership statistics for 137 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 137 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 12% |
| Student > Bachelor | 16 | 12% |
| Other | 15 | 11% |
| Researcher | 14 | 10% |
| Student > Ph. D. Student | 13 | 9% |
| Other | 27 | 20% |
| Unknown | 35 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 72 | 53% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 7% |
| Nursing and Health Professions | 4 | 3% |
| Social Sciences | 3 | 2% |
| Biochemistry, Genetics and Molecular Biology | 2 | 1% |
| Other | 8 | 6% |
| Unknown | 38 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 January 2022.
All research outputs
#3,155,860
of 25,703,943 outputs
Outputs from Acta Diabetologica
#100
of 1,040 outputs
Outputs of similar age
#55,115
of 383,305 outputs
Outputs of similar age from Acta Diabetologica
#3
of 13 outputs
Altmetric has tracked 25,703,943 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,040 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 383,305 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.